This page respects the original work's rights terms and independently introduces its bibliography, abstract, main results, and limitations. It is not a full translation.
About this resource
This page introduces a 2017 randomized trial that added purified cannabidiol (CBD) to standard antiseizure treatment for drug-resistant seizures in Dravet syndrome, a severe genetic epilepsy. The 120 participants, aged 2–18 years, were assigned to CBD or placebo. The trial evaluated a research pharmaceutical with controlled composition and quality, not the cannabis plant or general commercial CBD products.
Dravet syndrome is a serious condition that may involve frequent seizures and developmental effects. The principal question was whether convulsive-seizure frequency changed over a defined period relative to placebo while existing treatment continued. The design did not directly establish complete seizure resolution or improvement in long-term development.
Study design
After seizure frequency was recorded during a baseline period, participants received purified CBD or matching placebo for 14 weeks. Patients, families, and researchers were blinded. The primary outcome was the change in monthly convulsive-seizure frequency from the baseline period to the treatment period. All seizures, caregivers’ ratings of overall change, and adverse events were also recorded.
Other antiseizure medications generally continued, so CBD was not monotherapy. Interactions with concomitant medications may affect blood concentrations and adverse events, making it difficult to isolate every finding simply as an effect of CBD alone.
Content
Unlike THC, CBD is not primarily used for the characteristic psychoactive effects of cannabis. Yet “less psychoactive” does not mean an absence of pharmacological effects or interactions. CBD affects hepatic metabolic enzymes, and concentrations of metabolites are known to change when it is combined with certain antiseizure medications.
The research involved rigorous diagnosis, seizure records, and medical monitoring. Purity, exposure, measurement, and emergency response differ substantially from circumstances in which families adjust commercial products themselves.
Results
Median convulsive-seizure frequency changed from 12.4 to 5.9 per month in the CBD group and from 14.9 to 14.1 in the placebo group. The adjusted between-group difference favored CBD, and the proportions of participants with at least a 50% reduction in seizure frequency were also compared. Many participants nevertheless continued to have seizures, and responses differed among individuals.
Adverse events were reported more often in the CBD group and included somnolence, diarrhea, decreased appetite, fatigue, vomiting, fever, lethargy, and abnormal liver-function test results. Some events led to trial discontinuation, demonstrating the need to monitor harms as well as benefits.
Limitations
The trial period was short and could not adequately assess long-term seizure control, development, quality of life, or effects on growth. The findings concern one specific rare epilepsy syndrome and cannot be extrapolated to other epilepsies, pain, anxiety, or general health purposes.
Caregiver seizure records may contain measurement error. Types and concentrations of concomitant medications can also affect efficacy and adverse events. Funding and preparation-supply relationships should be reviewed in the original disclosure.
Safety
The CBD in this trial was pharmaceutical grade and used in a medical setting that monitored liver function and concomitant medications. Commercial CBD products may differ in content, contamination, and THC presence, so this trial cannot guarantee their outcomes. Changing or discontinuing antiseizure medication without clinical supervision may lead to worsening seizures and serious consequences.
Specialist management is essential for children and young people with drug-resistant seizures who use multiple medications. This page provides no guidance on amounts, administration, or product selection and does not replace medical judgment with trial findings.
Source and rights
Original source: Devinsky O, et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. The New England Journal of Medicine. 2017;376:2011–2020. DOI: 10.1056/NEJMoa1611618.
Respecting the publisher’s copyright, this page is a detailed introduction that independently summarizes the study design, results, safety, and limitations based on public bibliographic information and the abstract. It is not a full translation or republication of figures and tables.